Tampa VA Lung Precision Oncology Program (LPOP)

The Lung Precision Oncology Program (LPOP) has the stated mission of improving care for all the nation's Veterans who have been diagnosed with lung cancer. In developing this nationwide LPOP program, VA has selected locations across the country to serve as central Hub sites, which work together with local VA facilities on screening, genetic testing, and participation in clinical trials. VA LPOP ensures that Veterans have access to cutting-edge cancer care no matter where they live.

James A. Haley Veterans’ Hospital is proud to be part of VHA’s Precision Oncology Initiative, aiming to continue to create a system of excellence in oncology care. To accomplish this goal, LPOP has assembled experts in pulmonology, oncology, thoracic surgery, radiation oncology, radiology, pathology and translational sciences here at JAHVH and around the country to ensure that we can make a difference in the battle against lung cancer. Through timely lung cancer screening programs, smoking cessation education and cutting-edge clinical trials, we are happy to say that we're closer to that goal than ever.

Program goals include:

• Increasing screening to detect lung cancer sooner in Veterans at risk
• Offering genetic testing for Veterans with lung cancer
• Providing Veterans with lung cancer access to unique, new treatment options and precision oncology trials
• Integrating new knowledge into lung cancer care

While great progress has been made, Veterans need more and better options. Precision oncology means matching the right treatment to the right patient using a molecular understanding of their cancer. Our focus is to provide targeted cancer care for veterans while facilitating access to investigational therapies through clinical trials.

GRAIL: REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program Galleri

Screening study for multiple cancers

This is a population study that uses the Galleri blood test to check for the presence of cancer, as well as the type of cancer. This study looks to determine if the Galleri multi-cancer early detection test will improve general health measures by checking for more than 50 cancers through a simple blood draw.

For more information, please contact

Stefanie Gonzalez, Stephanie.Gonzalez2@va.gov,

Adam Zoble, Adam.Zoble@va.gov,

____________

NIGHTINGALE: CliNIcal Utility of ManaGement of Patients witH CT and LDCT Identified Pulmonary Nodules UsinG the Percepta NasAL Swab ClassifiEr – with Familiarization

Screening study for pulmonary nodule biomarkers

This study is designed to develop a minimally-invasive test to better determine a person’s risk for lung cancer. Results may allow doctors to either avoid unnecessary testing for individuals that are considered low risk or expedite testing for high risk Veterans. 

For more information, please contact

Precious Leaks-Gutierrez atPrecious.Leaks-Gutierrez2@va.gov,

______________

NOBLE: NOse Brushing for Lung Cancer Assessment in Epithelium

Screening study for pulmonary nodule biomarkers   

This study is designed to develop a biomarker test to aid in monitoring a person’s risk for lung cancer risk instead of LDCT for nodules identified for long-term monitoring by CT.

For more information, please contact

Precious Leaks-Gutierrez at Precious.Leaks-Gutierrez2@va.gov,

_________________

MIRATI: Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in patients with advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Treatment study for advances metastatic cancer with KRAS G12C mutation

The phase 2 portion of “MIRATI” is a clinical study for patients with locally advanced non-small cell lung cancer that have the KRAS G12C mutation. The goal of this study is to evaluate safety and efficacy of the investigational MRTX849 monotherapy, in combination with KEYTRUDA, as a potential first-line treatment for this type of lung cancer.

For more information, please contact

Precious Leaks-Gutierrez at  Precious.Leaks-Gutierrez2@va.gov,